Endothelin and endothelin receptor antagonists in heart failure

Congestive Heart Failure

Volumn 8, Issue 5, 2002, Pages 257-261

  Greenberg, Barry H ^a  

^a UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENDOTHELIN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; NEUROHORMONE; TEZOSENTAN;

ANIMAL MODEL; CELL GROWTH; CELL STIMULATION; CLINICAL TRIAL; DRUG EFFECT; FIBROBLAST; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE TACHYCARDIA; HORMONE RELEASE; HUMAN; HYPOTENSION; LIVER TOXICITY; NONHUMAN; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PROTEIN STRUCTURE; RECEPTOR BLOCKING; REVIEW; VASOCONSTRICTION; VASODILATATION;

EID: 0036750149     PISSN: 10797998     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-5299.2002.01153.x     Document Type: Review

References (45)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
2. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.
3. Inoue A, Yanagisawa M, Takuwa Y, et al. The human pre-proendothelin-1 gene: complete nucleotide sequence and regulation of expression. J Biol Chem. 1989;264(25):14954-14959.
4. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 1989;86: 2863-2867.
5. Yoshizumi M, Kurihara H, Sugiyama T, et al. Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem Biophys Res Commun. 1989;161(2): 859-864.
6. Macarthur H, Warner TD, Wood EG, et al. Endothelin-1 release from endothelial cells in culture is elevated both acutely and chronically by short periods of mechanical stretch. Biochem Biophys Res Commun. 1994;200:395-400.
7. Boulanger CM, Tanner FC, Bea ML, et al. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res. 1992;70:1191-1197.
8. Kourembanas S, Marsden PA, McQuillan LP, et al. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest. 1991;88:1054-1057.
9. Kohno M, Murakawa K, Yokokawa K, et al. Production of endothelin by cultured and porcine endothelial cells; modulation by adrenaline. J Hypertens. 1989;7(suppl):S130-S131.
10. Ohta K, Hirata Y, Imai T, et al. Cytokine-induced release of endothelin-1 from porcine renal epithelial cell line. Biochem Biophys Res Commun. 1990;169:578-584.
11. Kanse SM, Takahashi K, Lam HC, et al. Cytokine stimulated endothelin release from endothelial cells. Life Sci. 1991; 48:1379-1384.
12. Dohi Y, Hahn AW, Boulanger CM, et al. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypentension. 1992;19: 131-137.
13. Barton M, Shaw S, d'Uscio LV, et al. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin-converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun. 1997; 238:861-865.
14. Cavero P, Miller W, Heublein D, et al. Endothelin in experimental congestive heart failure in the anesthetized dog. Am J Physiol. 1990;259:F312-F317.
15. Cody R, Haas G, Binkley P, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504-509.
16. Pacher R, Bergler-Klein J, Globits S, et al. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systematic hypertension. Am J Cardiol. 1993;71;1293-1299.
17. Teerlink J, Löffler BM, Hess P, et al. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Circulation. 1994;90:2510-2518.
18. Sakai S, Miyauchi T, Sakurai T, et al. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. J Am Coll Cardiol. 1996;28:1580-1588.
19. Shubeita H, McDonough P, Harris A, et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. J Bio Chem. 1990;265:20555-20562.
20. Guarda E, Katwa L, Myers P, et al. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res. 1993;27:2130-2134.
21. Bogoyevitch M, Glennoin P, Andersson M, et al. Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. J Bio Chem. 1994;269:1110-1119.
22. Knuepfer MM, Han SP, Trapani AJ, et al. Regional hemodynamic and baroreflex effects of endothelin in rats. Am J Physiol. 1989;257:H918-H926.
23. van den Buuse M, Itoh S. Central effects of endothelin on baroreflex of spontaneously hypertensive rats. J Hypertens. 1993;11:379-387.
24. Kannan H, Tanaka H, Ueta Y, et al. Effects of centrally administered endothelin-3 on renal sympathetic nerve activity and renal blood flow in conscious rats. J Auton Nerv Syst. 1994;49:105-113.
25. Sorenson SS, Madsen JK, Pederson EB. Systematic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers. Am J Physiol. 1994;266:F411-F418.
26. Omland T, Lie R, Aakvaag A, et al. Plasma endothelin determination as a prognostic indicator of one-year mortality after acute myocardial infarction. Circulation. 1994;89:1573-1579.
27. Tsutamoto T, Wada A, Hisanaga T, et al. Relationship between endothelin-1 extraction in the peripheral circulation and systematic vascular resistance in patients with severe congestive heart failure. J Am Coll Cardiol. 1999;33(2):530-537.
28. MacCarthy P, Grocott-Mason R, Prendergast B, et al. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart. Circulation. 2000;101:142-147.
29. Nakao K, Arai H, Hosoda K, et al. Molecular cloning of two subtypes of human endothelin receptor. J Vascular Med Bio. 1991;3:303-307.
30. Molenaar P, O'Reilly G, Sharkey A, et al. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conduction system and myocardium. Circ Res. 1993;72:526-538.
31. Xu D, Emoto N, Giaid A, et al. ECE 1: a membrane-bound metalloproteinase that catalyzes the proteolytic activation of big endothelin-1. Cell. 1994;78:473-485.
32. Tsurumi Y, Fujie K, Niskikawa M, et al. Biological and pharmacological properties of highly selective new endothelin converting enzyme inhibitor WS 79089B isolated from streptosporangeum useum no. 79089. J Antibiot (Tokyo). 1995;48(2):169-174.
33. Ito H, Hiroe M, Hirata Y, et al. Endothelin ET-A receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation. 1994;89:2198-2203.
34. Saad D, Mukherjee R, Thomas P, et al. The effects of endothelin-A receptor blockade during the progression of pacing-induced congestive heart failure. J Am Coll Cardiol. 1998;32: 1779-1786.
35. Mishima T, Tanimura M, Suzuki G, et al. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol. 2000;35:222-229.
36. Inada T, Fujiwara H, Hasegawa K, et al. Upregulated expression of cardiac endothelin-01 participates in myocardial cell growth in Bio14.6 syrian cardiomyopathic hamsters. J Am Coll Cardiol. 1999;33:565-571.
37. 2+ uptake. Circulation. 2000;102:1582-1588.
38. Teerlink JR, Loffler BM, Hess P, et al. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure: acute effects of the endothelin-receptor antagonist Ro 47-0203 (bosentan). Circulation. 1994;89: 2510-2518.
39. Greenberg B, Quinones M, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography sub-study. Circulation. 1995;91:2573-2581.
40. Sakai S, Miyauchi T, Kobayashi M, et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996;384:353-355.
41. Cowburn PJ, Cleland JG, McArthur JD, et al. Short-term hemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure (letter). Lancet. 1998;352:201-202.
42. Psieker LE, Mitrovic V, Noll G, et al. Acute hemodynamic and neurohumoral effects of selective ET(A)-receptor blockade in patients with congestive heart failure. J Am Coll Cardiol. 2000;35:1745-1752.
43. Torre-Amione G, Young JB, Durnad JB, et al. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation. 2001;103:973-980.
44. Packer M, Caspi A, Charlton V, et al. Multicenter, double-blind placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure-results of the REACH-1 trial. Circulation. 1998;98(suppl S):12.
45. Packer M. Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure [ENABLE] 1 and 2. Results presented at the American College of Cardiology 51st Annual Scientific Session. Atlanta, GA; March 17-20, 2002.